Leerink initiated coverage of United Therapeutics with an Outperform rating and $330 price target. The firm says it has conducted an extensive review of the company’s broad commercial portfolio that is primarily focused on treating different types of pulmonary hypertension, in addition to the probability of success and market opportunities of its PH expansion efforts and pipeline platforms. Backed by multiple MEDACorp KOL calls, Leerink believes United Therapeutics has a leading role in the PH space, which, paired with thoughtful strategic development, allows them to meaningfully grow its current Tyvaso franchise by driving Tyvaso DPI uptake and pursuing expansion efforts into pulmonary hypertension associated with interstitial lung disease, where it has first-mover advantage.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on UTHR:
- Liquidia files response and counterclaims to United Therapeutics lawsuit
- Biotech Alert: Searches spiking for these stocks today
- Liquidia price target raised to $30 from $15 at Ladenburg
- United stock negative reaction ‘discounting extreme scenarios,’ says Oppenheimer
- Wells Fargo sees limited fundamental impact to United following Liquidia ruling
Questions or Comments about the article? Write to editor@tipranks.com